Pharmacology, pharmacokinetic features and interactions of atazanavir

Enfermedades infecciosas y microbiología clínica
Luis F López-Cortés

Abstract

Atazanavir (ATV) is an HIV protease inhibitor (IP) with a high in vitro activity against HIV-1, that demonstrates a high additive activity in the presence of other antiretrovirals and a synergic activity with other PI. Oral absorption is greater than 68%, maximum concentration (C(max)) being reached approximately 2 to 3 h after its administration. Its absorption is dependent on gastric pH, its administration being recommended after meals. The pharmacokinetics (PK) of ATV are non-linear; that is to say, its plasma concentrations (C(p)) do not increase in proportion to the dose. ATV is approximately 86% bound to plasma proteins. Its entry into the cerebrospinal fluid, semen or genital secretions varies but is generally less than 10-20%. Its passage across the placenta, measured as the mean of the ratios between the C(p) in umbilical cord and maternal blood, is 0.13. ATV is metabolised by oxidation by cytochrome P450 enzymes, subsequently being eliminated by the bile duct in the free or glucuronide form (80%) and by the urine. ATV is a weak competitive inhibitor of CYP3A4 and a strong inhibitor of uridine diphosphate-glucuronosyltransferase 1A1, which is the cause of the frequent high plasma bilirubin after its administration and ...Continue Reading

References

Apr 15, 2004·Clinical Pharmacokinetics·Jennifer R KingEdward P Acosta
May 25, 2004·Antimicrobial Agents and Chemotherapy·Anne-Marie TaburetPierre-Marie Girard
Aug 27, 2005·British Journal of Clinical Pharmacology·John E RayAndrew J McLachlan
Sep 24, 2005·Clinical Pharmacokinetics·Clotilde Le TiecAnne-Marie Taburet
Mar 17, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Kari J FurtekMark R Wallace
Apr 6, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kirk M Chan-Tack, Anthony Edozien
Jun 10, 2006·European Journal of Clinical Pharmacology·Eric DaillyPascale Jolliet
Jul 25, 2006·Expert Opinion on Pharmacotherapy·Thomas N Kakuda, Jennifer J Kiser
Aug 31, 2006·Antimicrobial Agents and Chemotherapy·Sara ColomboChantal Csajka
Sep 14, 2006·The Annals of Pharmacotherapy·Eric G Sahloff, Joan M Duggan
Sep 29, 2006·Antimicrobial Agents and Chemotherapy·D M BurgerR Bertz
Nov 1, 2006·Antimicrobial Agents and Chemotherapy·E van LeeuwenJ M Prins
Feb 14, 2007·Antimicrobial Agents and Chemotherapy·Nils von HentigSchlomo Staszewski
Jun 20, 2007·Antimicrobial Agents and Chemotherapy·Edward P AcostaDavid W Haas
Aug 1, 2007·European Journal of Clinical Pharmacology·Nils von HentigSebastian Harder
Aug 21, 2007·The Journal of Antimicrobial Chemotherapy·R M M CleijsenD M Burger
Mar 26, 2008·British Journal of Clinical Pharmacology·Samantha AbelGary J Muirhead

❮ Previous
Next ❯

Citations

Dec 1, 2008·Enfermedades infecciosas y microbiología clínica·Antonio Rivero
Dec 1, 2008·Enfermedades infecciosas y microbiología clínica·Esteban Ribera Pascuet, Adrià Curran

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Related Papers

Enfermedades infecciosas y microbiología clínica
R PalaciosJesús Santos
Enfermedades infecciosas y microbiología clínica
Antonio Antela López
Enfermedades infecciosas y microbiología clínica
Santiago MorenoFernando Dronda
Enfermedades infecciosas y microbiología clínica
Joaquín PortillaSergio Reus
Enfermedades infecciosas y microbiología clínica
Laura Zamora, Jose Gatell
© 2021 Meta ULC. All rights reserved